Your browser doesn't support javascript.
loading
Inclusion-body myositis associated with Sjögren's disease: clinical characteristics and comparison with other Sjögren-associated myositis.
Astouati, Quentin; Machet, Thomas; Houssais, Camille; Noury, Jean-Baptiste; Allenbach, Yves; Gallay, Laure; Quere, Baptiste; Assan, Florence; Benveniste, Olivier; Broner, Jonathan; Duffau, Pierre; Espitia, Alexandra; Grasland, Anne; Hayem, Gilles; Guern, Véronique Le; Martis, Nihal; Mariampillai, Kuberaka; Nocturne, Gaëtane; Mariette, Xavier; Meyer, Alain; Mulleman, Denis; Devauchelle-Pensec, Valérie; Collet, Aurore; Launay, David; Hachulla, Eric; Cornec, Divi; Guellec, Dewi; Sanges, Sébastien.
Afiliação
  • Astouati Q; CHU Lille, Département de Médecine Interne et Immunologie Clinique, Lille, F-59000, France.
  • Machet T; Centre National de Référence Maladies Auto-immunes Systémiques Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, F-59000, France.
  • Houssais C; Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET), Lille, F-59000, France.
  • Noury JB; CHU Lille, Département de Médecine Interne et Immunologie Clinique, Lille, F-59000, France.
  • Allenbach Y; Centre National de Référence Maladies Auto-immunes Systémiques Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, F-59000, France.
  • Gallay L; Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET), Lille, F-59000, France.
  • Quere B; Rheumatology Department, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINOM), CHU de Brest, Brest, France.
  • Assan F; Reference Centre for Neuromuscular Diseases AOC, University of Brest, Brest, France.
  • Benveniste O; LBAI, UMR1227, Univ Brest, Inserm, Brest, France.
  • Broner J; Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, APHP, Centre de Référence Maladies Neuro-Musculaires, Sorbonne University, France, Centre de Recherche en Myologie INSERM-Association Institut de Myologie, UMRS 974, Paris, France.
  • Duffau P; Department of Internal Medicine and Clinical Immunology, Edouard Herriot University Hospital, Hospices Civils de Lyon, University Claude Bernard, Lyon, France.
  • Espitia A; Rheumatology Department, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINOM), CHU de Brest, Brest, France.
  • Grasland A; LBAI, UMR1227, Univ Brest, Inserm, Brest, France.
  • Hayem G; Laboratory of Genetic Skin Diseases, Institut Imagine, INSERM UMR 1163, Paris.
  • Guern VL; Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, APHP, Centre de Référence Maladies Neuro-Musculaires, Sorbonne University, France, Centre de Recherche en Myologie INSERM-Association Institut de Myologie, UMRS 974, Paris, France.
  • Martis N; Department of Internal Medicine, University Hospital of Nîmes, France.
  • Mariampillai K; Internal Medicine Department, Bordeaux University Hospital, FHU ACRONIM, Bordeaux, France. CNRS-UMR 5164 Immuno ConcEpT, Bordeaux University, Bordeaux, France.
  • Nocturne G; Department of Internal Medicine, Hôtel-Dieu, CHU de Nantes, France.
  • Mariette X; Department of Internal Medicine, Hôpital Louis Mourier, Université Paris Cité, AP-HP, Colombes, France.
  • Meyer A; Rheumatology Department, Paris Saint-Joseph Hospital, Paris, France.
  • Mulleman D; AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'île de France, Paris, France.
  • Devauchelle-Pensec V; Department of Internal Medicine, CHU Nice, France. Côte d'Azur University. Mediterranean Centre for Molecular Medicine, Control of gene expression (COdEX), INSERM U1065.
  • Collet A; Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, APHP, Centre de Référence Maladies Neuro-Musculaires, Sorbonne University, France, Centre de Recherche en Myologie INSERM-Association Institut de Myologie, UMRS 974, Paris, France.
  • Launay D; Department of Rheumatology, Université Paris-Saclay, AP-HP, Hôpitaux Universitaires Paris-Saclay, Centre for Immunology of Viral Infections and Autoimmune Diseases, INSERM UMR1184, Le Kremlin Bicêtre, France.
  • Hachulla E; Department of Rheumatology, Université Paris-Saclay, AP-HP, Hôpitaux Universitaires Paris-Saclay, Centre for Immunology of Viral Infections and Autoimmune Diseases, INSERM UMR1184, Le Kremlin Bicêtre, France.
  • Cornec D; Department of Rheumatology, Strasbourg University Hospital, Centre de Référence des Maladies Auto-immunes Rares, Strasbourg, France.
  • Guellec D; University of Tours, EA6295 NMNS, Tours, France Department of Rheumatology, CHRU de Tours, Tours, France.
  • Sanges S; Rheumatology Department, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINOM), CHU de Brest, Brest, France.
Article em En | MEDLINE | ID: mdl-38430004
ABSTRACT

OBJECTIVES:

To describe the characteristics of patients with Sjögren's disease (SjD) and inclusion-body myositis (IBM), and how they compare to SjD patients with other inflammatory myopathies (IM).

METHODS:

Patients were retrospectively recruited from 13 French centers and included if they met the ACR/EULAR criteria for SjD and for IM. They were categorized as SjD-IBM if sub-criteria for IBM were met, or as SjD-other IM if not.

RESULTS:

SjD-IBM patients (n = 22) were mostly females (86%), with a median [Q1; Q3] age of 54 [38.5; 64] years at SjD diagnosis, and 62 [46.5; 70] years at first IBM symptoms. Although most patients displayed glandular and immunological abnormalities, additional extra-glandular manifestations were uncommon, resulting in moderate disease activity at SjD diagnosis (ESSDAI 5.5 [1; 7.8]). Classic IBM features were frequent, such as progressive symptom onset (59%), asymmetrical (27%) and distal (32%) involvements, dysphagia (41%), low CPK (386.5 [221.8; 670.5] UI/l) and CRP (3.0 [3; 8.5] mg/l) levels. Immunosuppressants were reported as efficient in 55% of cases.Compared with SjD-IBM patients, SjD patients with other IM (n = 50) were significantly younger, displayed more frequent additional extra-glandular disease, higher ESSDAI score (11 [3; 30]), shorter delay between SjD diagnosis and myositis onset (0 [-0.5; 26]), more frequent CPK values over 1000 UI/l (36%), and less frequent classic IBM features.

CONCLUSION:

IBM can occur in SjD patients, with muscle features reminiscent of classic sporadic IBM characteristics, but mostly affecting women. In SjD patients with muscle involvement, extra-glandular manifestations, high ESSDAI score, elevated CPK values, and shorter delay after SjD diagnosis plead against IBM.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França